Yun Jee Seo

TL;DR: Single-cell RNA-seq on viable PDX cells identified a candidate tumor cell subgroup associated with anti- cancer drug resistance, a powerful approach for identifying unique tumor cell-specific gene expression profiles which could facilitate the development of optimized clinical anti-cancer strategies.

TL;DR: It is shown that evolutionary inference from integrated genomic analysis in multisector biopsies can inform targeted therapeutic interventions for patients with GBM and that targeting truncal events is more efficacious than targeting private events in reducing the tumor burden.

TL;DR: Analysis of genomic and transcriptomic data from 462 patient-derived tumor cell (PDC) samples across 14 cancer types, along with pharmacological responses to 60 agents, indicates that PDC-derived drug sensitivities might be predictive of clinical response to targeted therapies.

TL;DR: Results indicate that the FoxM 1-Sox2 signaling axis promotes clonogenic growth and radiation resistance of GBM, and suggest that FoxM1 targeting combined with irradiation is a potentially effective therapeutic approach for GBM.

TL;DR: A micropillar/microwell chip platform is developed, ideally suited for encapsulating primary cancer cells in nanoscale spots of hydrogels on the chip, generating efficacy data with various drugs, eventually allowing for a comparison of the in vitro data obtained from the chip with clinical data as well as gene expression data.